Virax Biolabs Group Limited Ordinary Shares (VRAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Virax Biolabs Group Limited Ordinary Shares (VRAX) has a cash flow conversion efficiency ratio of -0.576x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.92 Million) by net assets ($5.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VRAX company net worth for the company's overall valuation and market capitalisation.
Virax Biolabs Group Limited Ordinary Shares - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Virax Biolabs Group Limited Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Virax Biolabs Group Limited Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Virax Biolabs Group Limited Ordinary Shares ranked by their cash flow conversion efficiency. See Virax Biolabs Group Limited Ordinary Sha cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dixie Gold Inc
V:DG
|
-0.501x |
|
CT UK High Income Ord
LSE:CHI
|
0.007x |
|
GCP Asset Backed Income Fund Limited
LSE:GABI
|
0.107x |
|
Bridge Saas Ltd
AU:BGE
|
0.026x |
|
Baumart Holdings Ltd
AU:BMH
|
-0.258x |
|
Scinai Immunotherapeutics Ltd
NASDAQ:SCNI
|
-0.123x |
|
Peel Hunt Ltd
LSE:PEEL
|
0.134x |
|
Investment Friends Capital SE
WAR:IFC
|
0.002x |
Annual Cash Flow Conversion Efficiency for Virax Biolabs Group Limited Ordinary Shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Virax Biolabs Group Limited Ordinary Shares from 2020 to 2025. View VRAX stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $5.46 Million | $-4.56 Million | -0.835x | +31.27% |
| 2024-03-31 | $5.14 Million | $-6.25 Million | -1.216x | -158.97% |
| 2023-03-31 | $8.90 Million | $-4.18 Million | -0.469x | -169.43% |
| 2022-03-31 | $-1.20 Million | $-809.07K | 0.676x | -10.96% |
| 2021-03-31 | $-777.32K | $-590.19K | 0.759x | +23.90% |
| 2020-03-31 | $-1.22 Million | $-744.61K | 0.613x | -- |
About Virax Biolabs Group Limited Ordinary Shares
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, ot… Read more